A Systems Biology- and Machine Learning-Based Study to Unravel Potential Therapeutic Mechanisms of Midostaurin as a Multitarget Therapy on FLT3-Mutated AML

Acute myeloid leukemia (AML), a hematologic malignancy that results in bone marrow failure, is the most common acute adults. The presence of FMS-related tyrosine kinase 3 (FLT3) mutations associated with poor prognosis, making evaluation FLT3-inhibitors an imperative goal clinical trials. Midostaurin was first FLT3-inhibitor approved by FDA and EMA for treatment FLT3-mutated AML, it showed significant improvement overall survival newly diagnosed patients treated midostaurin, combination standard chemotherapy (RATIFY study). main interest midostaurin has been FLT3-specific inhibition, but little known about its role as multikinase inhibitor whether may be used relapse maintenance therapy. Here, we systems biology- machine learning-based approaches to deepen potential benefits multitarget activity better understand anti-leukemic effect on AML. resulting silico study revealed play treatment’s efficacy. Additionally, propose series molecular mechanisms support benefit therapy regulating microenvironment. obtained are backed up using independent gene expression data.